Skip to Main Content

Author Details

Elai Davicioni
Veracyte Inc.
2006
224
58
PMIDPaper TitleJournal TitlePublished Year
37474400Transcriptomic Heterogeneity of Expansile Cribriform and Other Gleason Pattern 4 Prostate Cancer Subtypes.Eur Urol Oncol2024
37562825F-SHARP: a Phase I/II trial of focal salvage high-dose-rate brachytherapy for Radiorecurrent prostate cancer.BJU Int2024
36367998Phase II Randomized Study of Salvage Radiation Therapy Plus Enzalutamide or Placebo for High-Risk Prostate-Specific Antigen Recurrent Prostate Cancer After Radical Prostatectomy: The SALV-ENZA Trial.J Clin Oncol2023
37595184Transcriptomic Signatures Associated With Outcomes in Recurrent Prostate Cancer Treated With Salvage Radiation, Androgen-Deprivation Therapy, and Enzalutamide: Correlative Analysis of the STREAM Trial.JCO Precis Oncol2023
37525535Use of the Decipher genomic classifier among men with prostate cancer in the United States.JNCI Cancer Spectr2023
37958414Clinical-Genomic Risk Group Classification of Suspicious Lesions on Prostate Multiparametric-MRI.Cancers (Basel)2023
37857524Analysing the tumor transcriptome of prostate cancer to predict efficacy of Lu-PSMA therapy.J Immunother Cancer2023
37700560Transcriptomic analyses of localized prostate cancers of East Asian and North American men reveal race-specific luminal-basal and microenvironmental differences.Cancer Commun (Lond)2023
37870965Genomic Tumor Correlates of Clinical Outcomes Following Organ-Sparing Chemoradiation Therapy for Bladder Cancer.Clin Cancer Res2023
35568781High intratumoral plasma cells content in primary prostate cancer defines a subset of tumors with potential susceptibility to immune-based treatments.Prostate Cancer Prostatic Dis2023
37060201A novel prostate cancer subtyping classifier based on luminal and basal phenotypes.Cancer2023
37205576Radiogenomic profiling of prostate tumors prior to external beam radiotherapy converges on a transcriptomic signature of TGF-β activity driving tumor recurrence.medRxiv2023
37137444Genomic Classifier Performance in Intermediate-Risk Prostate Cancer: Results From NRG Oncology/RTOG 0126 Randomized Phase 3 Trial.Int J Radiat Oncol Biol Phys2023
37331778Histology Specific Molecular Biomarkers: Ushering in a New Era of Precision Radiation Oncology.Semin Radiat Oncol2023
37164128Transcriptomic and clinical heterogeneity of metastatic disease timing within metastatic castration-sensitive prostate cancer.Ann Oncol2023
36522269Distinct Profiles of DNA Repair Activity Define Favorable-risk Prostate Cancer Subtypes With Divergent Outcome.Clin Genitourin Cancer2023
36621992Reply by Authors.J Urol2023
36621991Pathological Effects of Apalutamide in Lower-risk Prostate Cancer: Results From a Phase II Clinical Trial.J Urol2023
36743402Prostate Cancer Tumor Volume and Genomic Risk.Eur Urol Open Sci2023
36397716Transcriptomic recurrence score improves recurrence prediction for surgically treated patients with intermediate-risk clear cell kidney cancer.Cancer Med2023
36870853Transcriptomic Heterogeneity in High-risk Prostate Cancer and Implications for Extraprostatic Disease at Presentation on Prostate-specific Membrane Antigen Positron Emission Tomography.Eur Urol Oncol2023
36798177Clinical testing of transcriptome-wide expression profiles in high-risk localized and metastatic prostate cancer starting androgen deprivation therapy: an ancillary study of the STAMPEDE abiraterone Phase 3 trial.Res Sq2023
36596347Analysis of a Biopsy-Based Genomic Classifier in High-Risk Prostate Cancer: Meta-Analysis of the NRG Oncology/Radiation Therapy Oncology Group 9202, 9413, and 9902 Phase 3 Randomized Trials.Int J Radiat Oncol Biol Phys2023
36596346Genomic Classifiers in Personalized Prostate Cancer Radiation Therapy Approaches: A Systematic Review and Future Perspectives Based on International Consensus.Int J Radiat Oncol Biol Phys2023
33303244Novel Transcriptomic Interactions Between Immune Content and Genomic Classifier Predict Lethal Outcomes in High-grade Prostate Cancer.Eur Urol2022
35641377Corrigendum to: Mechanistic target of rapamycin (mTOR) protein expression in the tumor and its microenvironment correlates with more aggressive pathology at cystectomy.Urol Oncol2022
35638091Variation in Molecularly Defined Prostate Tumor Subtypes by Self-identified Race.Eur Urol Open Sci2022
35636621Validation of the Decipher genomic classifier in patients receiving salvage radiotherapy without hormone therapy after radical prostatectomy - an ancillary study of the SAKK 09/10 randomized clinical trial.Ann Oncol2022
35662504Transcriptomic Features of Cribriform and Intraductal Carcinoma of the Prostate.Eur Urol Focus2022
35562350MYC drives aggressive prostate cancer by disrupting transcriptional pause release at androgen receptor targets.Nat Commun2022
35657158Genomic biomarkers to guide precision radiotherapy in prostate cancer.Prostate2022
35681714Association between Incidental Pelvic Inflammation and Aggressive Prostate Cancer.Cancers (Basel)2022
36087093Increased MYBL2 expression in aggressive hormone-sensitive prostate cancer.Mol Oncol2022
36053178Genomic Testing in Localized Prostate Cancer Can Identify Subsets of African Americans With Aggressive Disease.J Natl Cancer Inst2022
35082164Antizyme Inhibitor 1 Regulates Matrikine Expression and Enhances the Metastatic Potential of Aggressive Primary Prostate Cancer.Mol Cancer Res2022
35050721Does Perioperative Testosterone Predict Post-Prostatectomy Genomic Risk Score?J Urol2022
34643090Patients with Muscle-Invasive Bladder Cancer with Nonluminal Subtype Derive Greatest Benefit from Platinum Based Neoadjuvant Chemotherapy.J Urol2022
34538726Subpathologies and genomic classifier for treatment individualization of post-prostatectomy radiotherapy.Urol Oncol2022
34226663A transcriptomic model for homologous recombination deficiency in prostate cancer.Prostate Cancer Prostatic Dis2022
32156491Clinical-genomic Characterization Unveils More Aggressive Disease Features in Elderly Prostate Cancer Patients with Low-grade Disease.Eur Urol Focus2021
35475294Impact of Decipher on use of post-operative radiotherapy: Individual patient analysis of two prospective registries.BJUI Compass2021
33570548Validation of a 22-Gene Genomic Classifier in Patients With Recurrent Prostate Cancer: An Ancillary Study of the NRG/RTOG 9601 Randomized Clinical Trial.JAMA Oncol2021
33712636A showcase study on personalized in silico drug response prediction based on the genetic landscape of muscle invasive bladder cancer.Sci Rep2021
33568675Plasma cells are enriched in localized prostate cancer in Black men and are associated with improved outcomes.Nat Commun2021
33928239Prostate cancer in young men represents a distinct clinical phenotype: gene expression signature to predict early metastases.J Transl Genet Genom2021
33785257Molecular Characterization of Residual Bladder Cancer after Neoadjuvant Pembrolizumab.Eur Urol2021
33840559Prostate-specific Membrane Antigen and Fluciclovine Transporter Genes are Associated with Variable Clinical Features and Molecular Subtypes of Primary Prostate Cancer.Eur Urol2021
33864110Expression of ISL1 and its partners in prostate cancer progression and neuroendocrine differentiation.J Cancer Res Clin Oncol2021
33531653A comparative study of PCS and PAM50 prostate cancer classification schemes.Prostate Cancer Prostatic Dis2021
34934057The long noncoding RNA H19 regulates tumor plasticity in neuroendocrine prostate cancer.Nat Commun2021
  • 1 - 50 of 224

Recommended Authors

Rohan Bareja
Case Western Reserve University
Career Start Year 2017
Number of shared co-authors 32
Michael Sigouros
Caryl and Israel Englander Institute for Precision Medicine
Career Start Year 2017
Number of shared co-authors 32
Vincent Huang
Ontario Institute for Cancer Research
Career Start Year 2016
Number of shared co-authors 34
Natalie Kurganovs
Australian Prostate Cancer Research Centre Epworth
Career Start Year 2015
Number of shared co-authors 14
Wei Yuan
The Institute for Cancer Research
Career Start Year 2015
Number of shared co-authors 29
Daniel H Hovelson
Michigan Center for Translational Pathology, University of Michigan ann arbor
Career Start Year 2014
Number of shared co-authors 33
Joshua Armenia
Oncology R&D
Career Start Year 2013
Number of shared co-authors 37
Ekaterina Olkhov-Mitsel
University of Toronto
Career Start Year 2012
Number of shared co-authors 12
Dan R Robinson
Michigan Center for Translational Pathology, University of Michigan ann arbor
Career Start Year 2011
Number of shared co-authors 44
Robert J Lonigro
Michigan Center for Translational Pathology, University of Michigan ann arbor
Career Start Year 2007
Number of shared co-authors 42
Verena Sailer
Institute for Pathology, University Hospital Schleswig-Holstein
Career Start Year 2007
Number of shared co-authors 27
Svitlana Tyekucheva
Dana-Farber Cancer Institute
Career Start Year 2006
Number of shared co-authors 19
Alok K Tewari
Dana-Farber Cancer Institute, Harvard Medical School
Career Start Year 2005
Number of shared co-authors 10
Adam Sharp
The Institute for Cancer Research
Career Start Year 2003
Number of shared co-authors 31
Adam Foye
University of California San Francisco
Career Start Year 2003
Number of shared co-authors 44
Daniel S Brewer
University of Washington, USA Institute for Stem Cell and Regenerative Medicine
Career Start Year 2003
Number of shared co-authors 25
Joel S Parker
Lineberger Cancer Center, University of North Carolina
Career Start Year 2002
Number of shared co-authors 11
Wassim Abida
Memorial Sloan Kettering Cancer Center
Career Start Year 2002
Number of shared co-authors 67
Tesa M Severson
Oncode Institute, The Netherlands Cancer Institute
Career Start Year 2002
Number of shared co-authors 32
David S Rickman
Meyer Cancer Center
Career Start Year 2001
Number of shared co-authors 40
Sooryanarayana Varambally
University of Alabama at Birmingham, USA O'Neal Comprehensive Cancer Center
Career Start Year 2001
Number of shared co-authors 25
Jiaoti Huang
Duke University School of Medicine
Career Start Year 2000
Number of shared co-authors 73
Lodewyk F A Wessels
University Medical Centre Mannheim, University of Heidelberg
Career Start Year 2000
Number of shared co-authors 14
H??l??ne Hovington
Centre de Recherche du CHU de Quebec-Universite Laval (axe Oncologie)
Career Start Year 1999
Number of shared co-authors 40
Hayley C Whitaker
University College London
Career Start Year 1999
Number of shared co-authors 22
Joshi J Alumkal
Rogel Cancer Center, University of Michigan ann arbor
Career Start Year 1999
Number of shared co-authors 80
Phillip G Febbo
Illumina Inc.
Career Start Year 1997
Number of shared co-authors 46
Robert Kim
University of California
Career Start Year 1996
Number of shared co-authors 27
Rosina T Lis
National Cancer Institute
Career Start Year 1992
Number of shared co-authors 63
Dominique Trudel
Institut du cancer de Montreal
Career Start Year 1985
Number of shared co-authors 37

Collaborators

Robert Jeffrey Karnes
Mayo Clinic
Co-authored papers 67
Felix Y Feng
UCSF Medical Center-Mount Zion
Co-authored papers 65
Nicholas Erho
GenomeDx Biosciences Inc.
Co-authored papers 62
Edward M Schaeffer
Northwestern University Feinberg School of Medicine
Co-authored papers 60
Robert B Den
Thomas Jefferson University Hospital
Co-authored papers 58
Mohammed Alshalalfa
University of Miami Miller School of Medicine/Sylvester Comprehensive Cancer Center
Co-authored papers 50
Yang Liu
Veracyte inc.
Co-authored papers 50
Ashley E Ross
Northwestern University
Co-authored papers 50
Eric A Klein
Cleveland Clinic
Co-authored papers 42
Daniel E Spratt
University Hospitals Seidman Cancer Center, Case Western Reserve University
Co-authored papers 40
Paul L Nguyen
Brigham and Women's Hospital and Dana Farber Cancer Institute, Harvard Medical School
Co-authored papers 30
Mandeep Takhar
GenomeDx Biosciences Inc.
Co-authored papers 27
Tamara L Lotan
Johns Hopkins University School of Medicine
Co-authored papers 24
Stephen J Freedland
Cedars-Sinai Medical Center
Co-authored papers 23
Bruce J Trock
Johns Hopkins University School of Medicine
Co-authored papers 19
Lucia L Lam
School of Clinical Medicine, University of Hong Kong, Queen Mary Hospital
Co-authored papers 19
Timothy J Triche
Center for Epigenetics, Van Andel Research Institute
Co-authored papers 18
Brandon A Mahal
Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine
Co-authored papers 17
Jeffrey J Tosoian
Vanderbilt University Medical Center
Co-authored papers 12
Alan Pollack
University of Miami Miller School of Medicine
Co-authored papers 12
Phuoc T Tran
University of Maryland School of Medicine
Co-authored papers 11
Jingbin Zhang
GenomeDx Biosciences Inc.
Co-authored papers 10
Colin C Collins
University of British Columbia
Co-authored papers 10
Timothy R Rebbeck
Center for Cancer Equity and Engagement, Dana-Farber/Harvard Cancer Center
Co-authored papers 9
Andrea Sboner
Institute for Computational Biomedicine
Co-authored papers 9
Tarek A Bismar
University of Calgary Cumming School of Medicine, Rockyview General Hospital
Co-authored papers 9
Arul M Chinnaiyan
University of Michigan Medical School.
Co-authored papers 8
Rohit Mehra
Michigan Center for Translational Pathology.
Co-authored papers 8
Varune R Ramnarine
University of British Columbia
Co-authored papers 7
Sheila Weinmann
Center for Health Research, Kaiser Permanente Northwest Research Center
Co-authored papers 7
Release 1.2